Modena submitted data on the booster injection of the new crown vaccine to the United States, saying that the delta antibody exceeded 40 times.In September local time, Moderna (mRNA. US), an American new crown vaccine research and development company, announced that it had begun to submit preliminary data to the U.S. Food and Drug Administration (FDA) to evaluate the effect of its 50 microgram dose of new crown vaccine mrna-1273 booster needle. In addition, Modena hopes to submit the data to the European Drug Administration (EMA) and other regulators around the world in the next few days.
Modena mentioned in the official statement that the current data show a strong antibody response against mutant strains including delta. An additional analysis showed that the enhanced dose of mrna-1273 at the dose level of 50 μ g induced a strong antibody response and significantly increased the geometric mean titer of all variants of interest, including 32 fold increase in beta (b.1.351), 43.6-fold increase in gamma and 42.3-fold increase in Delta (b.1.617.2).
Modena also said that the phase II study of the new crown vaccine mrna-1273 was revised, and the enhanced needle at the dose level of 50 μ g was provided to interested participants 6 months after the second injection. The results showed that after the third vaccination, all age groups, especially people aged 65 and over, reached a similar level of neutralization titer, The safety characteristics were similar to those observed in the previous two doses.
MRNA new crown vaccine booster injection has made progress in the United States.
The U.S. Department of health and human services (HHS) issued a statement that the United States will provide booster shots to people who have been vaccinated with two doses of mRNA new crown vaccine from September 20, provided that FDA independently evaluates and confirms the safety and effectiveness of the third dose of mRNA vaccines from Pfizer and Modena.
Earlier, on August 12, FDA approved the extension of the mRNA new crown vaccine jointly developed by Pfizer / biontech and the new crown vaccine developed by Modena to the emergency use authorization (EUA), allowing the third dose of booster vaccine to be vaccinated in some specific immunocompromised people.